Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 3, 2015, Pages 514-521.e4

  Drobne, David ^a   Bossuyt, Peter ^a   Breynaert, Christine ^a   Cattaert, Tom ^a   Vande Casteele, Niels ^a   Compernolle, Griet ^a   Jürgens, Matthias ^a   Ferrante, Marc ^a   Ballet, Vera ^a   Wollants, Willem Jan ^a   Cleynen, Isabelle ^a   Van Steen, Kristel ^a   Gils, Ann ^a   Rutgeerts, Paul ^a   Vermeire, Severine ^a   Van Assche, Gert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Azathioprine; Inflammatory bowel disease; Methotrexate; Pharmacokinetic

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; DRUG ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; MERCAPTOPURINE; METHOTREXATE; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BELGIUM; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG EFFECT; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL; BELGIUM; CROHN DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925339415     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.07.027     Document Type: Article

References (20)

1. Cosnes J., Cattan S., Blain A., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
2. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010, 4:28-62.
3. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
4. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
5. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
6. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
7. Khan K.J., Dubinsky M.C., Ford A.C., et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011, 106:630-642.
8. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
9. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
10. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
11. Kotlyar D.S., Osterman M.T., Diamond R.H., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41.
12. Breynaert C., Ferrante M., Fidder H., et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011, 106:778-785.
13. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2008, 58:492-500.
14. Vande Casteele N., Buurman D.J., Sturkenboom M.G.G., et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012, 36:765-771.
15. R: a language and environment for statistical computing 2012, R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria.
16. Pinheiro J., Bates D., DebRoy S., et al. nlme: linear and nonlinear mixed effects models. R package version 3.1-105 2012, R Foundation for Statistical Computing, Vienna, Austria.
17. Therneau T. Apackage for survival analysis in S: R package version 2.36-14 2012, R Foundation for Statistical Computing, Vienna, Austria.
18. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
19. Ungar B., Chowers Y., Yavzori M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014, 63:1258-1264.
20. Louis E., Mary J.-Y., Vernier-Massouille G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70. quiz e31.